AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
=== Sugar profile === Honey is mainly fructose (51% of sugars) and glucose (44%) (table), with remaining sugars including galactose, maltose, and sucrose, each supplying 3% or less of total sugars (table, USDA reference). The glycemic index of honey has a possible range of 31–78, depending on the variety. The specific composition, color, aroma, and flavor of any batch of honey depend on the flowers foraged by bees that produced the honey.
Bilberries are non-climacteric berries with a smooth, circular outline at the end opposite the stalk, whereas American blueberries retain persistent sepals there, leaving a rough, star-shaped pattern of five flaps. Bilberries grow singly or in pairs rather than in clusters, as American blueberries do, and American blueberries have more evergreen leaves. Bilberries are dark in colour, and often appear near black with a slight shade of purple.
Striker Ian Wright was booed off by supporters over his performance, which he responded to by criticising the crowd from the dressing room window. Wenger called for an urgent team meeting, where "home truths were spoken, fingers pointed, players were geed up." The squad dictated how the conversation went, which the senior defenders made it clear they wanted Vieira and Petit to provide cover.
Sources: en.wikipedia.org
=== Medicine === Ether was once used in pharmaceutical formulations. A mixture of alcohol and ether, one part of diethyl ether and three parts of ethanol, was known as "spirit of ether", Hoffman's Anodyne or Hoffman's Drops. In the United States this concoction was removed from the Pharmacopeia at some point prior to June 1917, as a study published by William Procter, Jr. in the American Journal of Pharmacy as early as 1852 showed that there were differences in formulation to be found between commercial manufacturers, between international pharmacopoeia, and from Hoffman's original recipe. It was also used to treat hiccups through instillation into the nasal cavity.
Many variations of condensation reactions exist. Common examples include the aldol condensation and the Knoevenagel condensation, which both form water as a by-product, as well as the Claisen condensation and the Dieckman condensation (intramolecular Claisen condensation), which form alcohols as by-products.
=== Withdrawal === Users of hydromorphone may experience painful symptoms if the drug is suspended. Some people cannot tolerate the symptoms, which results in continuous drug use. Symptoms of opioid withdrawal are not easy to decipher, as there are differences between drug-seeking behaviors and true withdrawal effects. Symptoms associated with hydromorphone withdrawal include:
Sources: en.wikipedia.org
In order to remove the thin and well preserved skin slices and strips from the donor, surgeons use a special surgical instrument called a dermatome. This usually produces a split-thickness skin graft, which contains the epidermis with only a portion of the dermis. The dermis left behind at the donor site contains hair follicles and sebaceous glands, both of which contain epidermal cells which gradually proliferate out to form a new layer of epidermis. The donor site may be extremely painful and vulnerable to infection. There are several ways to treat donor site pain. These include subcutaneous anesthetic agents, topical anesthetic agents, and certain types of wound dressings.
In Brazil, regulations on traditional markets are handled at the municipal level. The regulations widely vary across Brazil, with zoning rules prohibiting such markets in some municipalities. A 2003 study found that traditional markets were losing ground in food retail to supermarkets, which had an overall food retail market share of 75%. The gains of supermarkets over traditional food retailers in Brazil were predominantly in meat and seafood retail, with the supermarkets' fresh meat & seafood market shares typically three times greater than their fresh fruits & vegetables market share.
==== Cytoplasmic transcription and replication ==== Once in the cytoplasm, the SeV genomic RNA is getting involved, as a template, in two different RNA synthetic processes performed by RNA-dependent RNA polymerase, which consists of L and P proteins: (1) transcription to generate mRNAs and (2) replication to produce a positive-sense antigenome RNA that in turn acts as a template for production of progeny negative-strand genomes. RNA-dependent RNA polymerase promotes the generation of mRNAs methylated cap structures. The NP protein is thought to have both structural and functional roles This protein concentration is believed to regulate the switch from RNA transcription to RNA replication. The genomic RNA functions as the template for the viral RNA transcription until the NP protein concentration increases. As the NP protein accumulates, the transition from the transcription to the replication occurs. The NP protein encapsidates the genomic RNA, forming a helical nucleocapsid which is the template for RNA synthesis by the viral RNA polymerase. The protein is a crucial component of the following complexes NP-P (P, phosphoprotein), NP-NP, nucleocapsid-polymerase, and RNA-NP. All these complexes are needed for the viral RNA replication. Research has demonstrated that de novo synthesis of the NP and P proteins is essential for efficient viral transcription. Studies using SeV mutants deficient in NP or P proteins, with genome replication disabled, revealed that the P protein is necessary for viral gene expression.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.